| Reduced exposure to calcineurin inhibitors in renal transplantation H Ekberg, H Tedesco-Silva, A Demirbas, Š Vítko, B Nashan, A Gürkan, ... New England Journal of Medicine 357 (25), 2562-2575, 2007 | 2175 | 2007 |
| Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation H Ekberg, C Bernasconi, H Tedesco-Silva, S Vítko, C Hugo, A Demirbas, ... American journal of transplantation 9 (8), 1876-1885, 2009 | 401 | 2009 |
| Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data GA Knoll, MB Kokolo, R Mallick, A Beck, CD Buenaventura, R Ducharme, ... Bmj 349, 2014 | 334 | 2014 |
| Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial T van Gelder, HT Silva, JW de Fijter, K Budde, D Kuypers, G Tyden, ... Transplantation 86 (8), 1043-1051, 2008 | 331 | 2008 |
| Everolimus plus reduced‐exposure CsA versus mycophenolic acid plus standard‐exposure CsA in renal‐transplant recipients HT Silva Jr, D Cibrik, T Johnston, E Lackova, K Mange, C Panis, R Walker, ... American Journal of Transplantation 10 (6), 1401-1413, 2010 | 322 | 2010 |
| Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies S Vitko, H Tedesco, J Eris, J Pascual, J Whelchel, JC Magee, S Campbell, ... American Journal of Transplantation 4 (4), 626-635, 2004 | 298 | 2004 |
| Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study MI Lorber, S Mulgaonkar, KMH Butt, E Elkhammas, R Mendez, ... Transplantation 80 (2), 244-252, 2005 | 295 | 2005 |
| FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation H Tedesco-Silva, G Mourad, BD Kahan, JG Boira, W Weimar, ... Transplantation 77 (12), 1826-1833, 2004 | 278 | 2004 |
| Everolimus with reduced calcineurin inhibitor exposure in renal transplantation J Pascual, SP Berger, O Witzke, H Tedesco, S Mulgaonkar, Y Qazi, ... Journal of the American Society of Nephrology 29 (7), 1979-1991, 2018 | 251 | 2018 |
| One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients HT Silva Jr, HC Yang, M Abouljoud, PC Kuo, K Wisemandle, ... American journal of transplantation 7 (3), 595-608, 2007 | 217 | 2007 |
| Mycophenolate Mofetil Substitution for Cyclosporine A in Renal Transplant Recipients with Chronic Progressive Allograft Dysfunction: The “Creeping Creatinine” Study1 C Dudley, E Pohanka, H Riad, J Dedochova, P Wijngaard, C Sutter, ... Transplantation 79 (4), 466-475, 2005 | 211 | 2005 |
| Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure EF Campos, H Tedesco-Silva, PG Machado, M Franco, ... American journal of transplantation 6 (10), 2316-2320, 2006 | 191 | 2006 |
| Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study BK Krämer, B Charpentier, L Bäckman, HT Silva Jr, ... American journal of transplantation 10 (12), 2632-2643, 2010 | 186 | 2010 |
| COVID-19 pandemic and worldwide organ transplantation: a population-based study O Aubert, D Yoo, D Zielinski, E Cozzi, M Cardillo, M Dürr, ... The Lancet Public Health 6 (10), e709-e719, 2021 | 179 | 2021 |
| Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year F Vincenti, HT Silva, S Busque, P O’connell, J Friedewald, D Cibrik, ... American journal of transplantation 12 (9), 2446-2456, 2012 | 172 | 2012 |
| Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range JM Kovarik, B Kaplan, HT Silva, BD Kahan, J Dantal, S Vitko, R Boger, ... Transplantation 73 (6), 920-925, 2002 | 171 | 2002 |
| Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses H Tedesco-Silva, C Felipe, A Ferreira, M Cristelli, N Oliveira, ... American Journal of Transplantation 15 (10), 2655-2664, 2015 | 162 | 2015 |
| Everolimus plus early tacrolimus minimization: a phase III, randomized, open‐label, multicentre trial in renal transplantation RM Langer, R Hene, S Vitko, M Christiaans, H Tedesco‐Silva Jr, ... Transplant International 25 (5), 592-602, 2012 | 147 | 2012 |
| 12‐month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients H Tedesco‐Silva Jr, S Vitko, J Pascual, J Eris, JC Magee, J Whelchel, ... Transplant International 20 (1), 27-36, 2007 | 135 | 2007 |
| Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation D Cibrik, HT Silva Jr, A Vathsala, E Lackova, C Cornu-Artis, RG Walker, ... Transplantation 95 (7), 933-942, 2013 | 130 | 2013 |
